NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cogent Biosciences, Inc. (COGT) Stock Analysis

Cogent Biosciences, Inc. (COGT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

COGT

$34.76

−$0.19 (−0.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COGT with… →

COGT Key Statistics

As of Sep 4, 2026
Trading
Open
$34.56
Previous Close
$34.95
Day's Range
34.42–35.20
52-Week Range
11.60–43.73
Volume
784.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.31
Valuation
Market Cap
$6.03B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$328.94M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
173.52M
1-Year Return
+168.62%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
2.31M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COGT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.14%
2025+355.38%
2024+32.65%
2023−49.13%
2022+34.73%
2021−23.60%
2020+289.93%
2019−83.64%
2018 (partial year)−60.40%

As of September 4, 2026.

COGT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$328.94M—
2024$0.00−$255.86M—
2023$0.00−$192.41M—
2022$0.00−$140.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$333.36M−$328.94M—
2024$0.00—−$275.94M−$255.86M—
2023$0.00—−$208.13M−$192.41M—
2022$0.00—−$147.84M−$140.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COGT Valuation vs Biotechnology Median

Median of 656 stocks
MetricCOGTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cogent Biosciences, Inc. (COGT) carries a market capitalisation of $6.03B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 258.

COGT last closed at $34.76 on September 4, 2026. That is −$0.19 (−0.54%) against the previous close. Over the past 52 weeks the price has ranged from $11.60 to $43.73. The latest close sits 199.66% above that 52-week low.

Financial Health

In fiscal 2025, Cogent Biosciences, Inc. reported revenue of $0.00. The same year closed with a net loss of $328.94M. The reported profit margin is 0%. Trailing earnings per share are −2.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +168.62%. Across 5 years the annualized return works out at +33.36%. The reported beta is 0.31. Daily returns over the trailing 8 years annualize to a volatility of 167.77%.

Growth & Income

The record shows no dividend for COGT.

Across the complete calendar years on file, 2025 returned +355.38% and 2019 returned −83.64%. Of the 7 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −2.14% year to date.

Peer Comparison

Cogent Biosciences, Inc. (COGT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cogent Biosciences, Inc. COGT $6.03B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cogent Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Visit website →